A Comparative Study of Dexamethasone versus Prednisone (Both in Combination with Melphalan) as Induction Therapy in Untreated Symptomatic Myeloma with an Additional Assessment of Dexamethasone versus no Additional Treatment as Maintenance Therapy in Non-Progressing Patients.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone; Melphalan; Prednisone
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

02 Apr 2020 Biomarkers information updated
11 Sep 2009 Actual end date (16 Jul 2003) added as reported by National Cancer Institute of Canada record.
16 Mar 2007 Status changed from in progress to completed. Actual number of patients added. Results reported.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight